Tag: MM

As a primary point of contact for patients, the role of the nurse is pivotal to the continuum of care. While this can be true for any patient, it is especially true for hematology patients undergoing immunotherapy.

In supporting the patient or caregiver, the nurse will assist countless times throughout the course of the patient journey. This assistance can take many forms, including discussions on disease-management options, consent, treatment, identification and monitoring of adverse events, and coordination of the multidisciplinary team. Because treatments are often administered in regional specialized centers, isolation and anxiety can add to an already uncertain future caused by a poor prognosis: The nurse becomes the patient's compass and ensures a comprehensive approach to a complex situation.

By giving more nurses greater access to the specialized immunotherapy knowledge and skills needed to actively role manage their patients, and by creating an online environment that nurtures a transparent exchange of ideas, information, and intelligence, we are helping more nurses to make a difference. We believe medical education should be for everyone. 

Immunotherapy Web Featured Images 122

CAR T-Cell Therapy Is Active, Safe in ALL

  Mar 09 2021 Tagged CAR-T, MM

Since the publication of the pivotal ELIANA trial in pediatric patients with acute lymphoblastic leukemia, the field of CAR T-cell therapy has grown significantly and left providers better equipped to understand and manage treatment-related adverse effects, such as cytokine release syndrome.

Visit website

Oncology Nursing News: CAR T-Cell Therapy Is Promising in Myeloma

Autologous and allogeneic BCMA-directed CAR T-cell therapies are leading to deep and durable responses in patients with heavily pretreated multiple myeloma, with a low incidence of severe cytokine release syndrome (CRS) and neurotoxicity, explained Yi Lin, MD, PhD, who added that with a pending biologics license application (BLA), the field should start to consider which patients, who don’t fit the typical clinical trial eligibility criteria, might be a candidate for the treatment in real-world practice.

Visit website
Immunotherapy Web Featured Images 51

Do mAbs and paraprotein affect COVID-19 Serological Testing in Patients with Mul...

  Dec 04 2020 Tagged mAbs, MM, COVID-19

SARS-CoV-2 (COVID-19) serology tests do not appear to interfere or cause cross-reactivity with therapeutic monoclonal antibody (t-mAb) treatments for hematologic malignancies (HM) such as multiple myeloma (MM), according to a study published in Diagnostics.

Read more

Promising Response Rates Build Excitement for CAR T-Cell Therapy in Myeloma

  Oct 31 2020 Tagged Nurses, CAR-T, MM

Anwer, an oncologist, physician-scientist, and stem cell transplant staff physician at the Taussig Cancer Center of Cleveland Clinic, discussed the growing role of CAR T-cell therapy in multiple myeloma and areas of unmet need. 

Visit website